STIFEL 2026 HEALTHCARE CONFERENCE - SYNDAX PHARMACEUTICALS INC

Financial Performance:

• RevuForge (Revumenib) demonstrated sequential growth in revenue, new patient starts, and treatment duration, with specific mention of a 20% sequential increase in new patient starts following an outlier in Q2.
• Niximvo (Nictivonib) reported 12% revenue growth, driven by patient expansion and extended duration of therapy in the third-line plus GVHD market.
• Net contribution from RevuForge is $22.6 million; gross margins for the portfolio are expanding, moving from the 25-30% range to 30-35%.
• Niximvo has captured approximately one-third of the third-line plus market, with growth targets focused on penetration and extending therapy duration.
• The company is aggressively pursuing profitability through disciplined spending and the commercial scaling of its heme franchise.

Guidance and Future Outlook:

• Management projects revenue acceleration in 2027 as the model reflects durable revenue from maintenance therapy post-transplant (expecting 70-80% of KMT2A patients to utilize maintenance).
• Niximvo is expected to continue growing as more patients are identified for transplant and subsequent maintenance, with data sets in the first half of 2025 expected to support frontline label expansion.
• The company aims to reach a frontline indication for Niximvo by 2028 via a pivotal trial, potentially with a steroid-sparing regimen.
• Long-term goals include expanding RevuForge into new lesions (e.g., NUP98) and leveraging the emerging pipeline (EGFR inhibitor and Next-Gen Menin) to drive future growth.

Business Segments and Product Lines:

• RevuForge (Revumenib): Dominant market leader in Relapsed/Refractory (R/R) AML for KMT2A and NPM1; commercial strategy shifting toward frontline combination trials (Venclexta/Venia and Intensive Chemotherapy).
• Niximvo (Nixitamab): Focused on GVHD; expanding into skin/lung lesions and evaluating combination with Ruxolitinib (data expected Q1 2025) to enable steroid-free frontline therapy.
• EGFR Inhibitor: Novel allosteric binder targeting the L858R mutation and atypical subtypes; IND submission expected year-end, with clinic initiation planned for Q1 2025; high CNS penetrance anticipated.
• Next-Gen Menin (Rev-62122): Optimized molecule for Myelofibrosis (MF) with activity against resistance mutations; proof-of-concept trials with RevuForge in MF starting late 2024/early 2025, with data expected in 2027.
• Pipeline Development: Maintain study (Dana-Farber collaboration) isolates maintenance contribution post-transplant; RAVEN study evaluates bridge-to-transplant strategies for fit patients.

Market and Competitive Landscape:

• Positioned as the market leader in R/R AML, citing 3+ years of data and a dominant position in combination therapies compared to newer entrants like J&J's BlexiMedib.
• Dismissed J&J's recent ASH abstract data as incomparable due to different treatment paradigms and less heavily pretreated patient populations in the competitor's study; emphasized Syndax's real-world combination data at ASH will demonstrate superior efficacy and tolerability.
• Niximvo is on track to match Resiroc's early-year sales trajectory ($500M in first 4 years) while aiming to expand the total addressable market (TAM) from 6,000 to 15,000-17,000 patients.
• Competitive frontline Menin studies (Evolve-2, Hovon) are designed to be more agile (30% smaller sample size) than peers, utilizing dual primary endpoints for accelerated approval potential.

Risks and Challenges:

• Patient identification and treatment initiation volatility remains a challenge, necessitating innovative outreach strategies to ensure consistent new patient starts.
• Potential "headwinds" in revenue visibility due to the complex model of patients exiting for transplant and returning for maintenance at variable timepoints; expected to stabilize and accelerate in 2027.
• Regulatory and commercial risks associated with launching steroid-free combination therapies and navigating compendia listings.
• Clinical execution risk for the EGFR inhibitor and Next-Gen Menin in novel indications (MF) despite promising preclinical data.

Management Commentary and Tone:

• Management tone is highly confident and optimistic, emphasizing strong commercial traction, data leadership at ASH, and a "pivotal time" for the company.
• Emphasis on "dominant position," "disciplined spending," and "highly differentiated assets."
• Leadership actively defends market share against competitors, highlighting the maturity of their data and the shift in the field toward combination therapies where they hold the advantage.
• CFO and CEO (Nick Botwood and Michael Metzger) demonstrated precise knowledge of clinical trial designs, enrollment momentum, and real-world data trends.

Analyst Questions and Answers:

• Competitor Efficacy (J&J): Management argued J&J's data is not directly comparable due to differences in patient pretreatment history and the evolving standard of care; highlighted Syndax's real-world combination data as more relevant.
• Frontline Trial Design: Explained the strategic rationale for two separate Phase 3 studies (fit vs. unfit) to optimize enrollment and statistical power, avoiding the "third arm" complexity of competitors by using separate randomized maintenance studies.
• Revenue Visibility: Addressed the Q2 outlier and explained that revenue growth is now driven by both new starts and extended duration via the transplant-maintenance cycle, which will fully materialize in 2027.
• Niximvo Growth Strategy: Discussed the potential for Ruxolitinib combination to drive frontline uptake and the plan to reduce steroid reliance, with data readouts expected in Q1 2025.

Other Key Points:

• ASH 2024 presentations will feature three key data sets: maintenance optimization (City of Hope), bridge-to-transplant efficacy, and early intervention via MRD relapse monitoring.
• The company is actively pursuing Business Development (BD) opportunities, having acquired most assets (except Next-Gen Menin) via BD, and intends to maintain a high bar for future acquisitions.
• RevuForge is pioneering the use of menin inhibitors in non-KMT2A/NPM1 lesions (e.g., NUP98) and Myelofibrosis (MF).
• The company has established international collaboration with CRO ParXL and Hovon for its Phase 3 trials, ensuring multi-hemisphere site activation.